MCID: HDG002
MIFTS: 44

Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards integrated aliases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

Name: Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance 12 15
Hodgkin Disease 44 72
Hodgkin Lymphoma, Lymphocytic-Histiocytic Predominance 12
Hodgkin's Disease, Lymphocyte Predominance 12
Lymphocyte Rich Classical Hodgkin Lymphoma 72
Hodgkin Lymphoma, Lymphocyte-Rich 12
Lymphocyte Rich Hodgkin's Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8543
ICD9CM 35 201.4
MeSH 44 D006689
NCIt 50 C6913
SNOMED-CT 68 59668005
ICD10 33 C81.4
UMLS 72 C0019829 C1266194

Summaries for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards based summary : Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance, also known as hodgkin disease, is related to lymphoma, hodgkin, classic and lymphosarcoma, and has symptoms including fever and night sweats. An important gene associated with Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance is B3GAT1 (Beta-1,3-Glucuronyltransferase 1), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and B cell receptor signaling pathway (KEGG). The drugs Epirubicin and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are homeostasis/metabolism and mortality/aging

Related Diseases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 33.2 PTPRC BCL6
2 lymphosarcoma 29.6 PTPRC BCL6
3 lymphoma, non-hodgkin, familial 29.5 PTPRC CR2 BCL6
4 reticulum cell sarcoma 29.2 PTPRC CR2
5 castleman disease 28.7 CR2 BCL6
6 classic hodgkin lymphoma, lymphocyte-rich type 12.9
7 lymphoma, hodgkin, x-linked pseudoautosomal 11.8
8 sarcoidosis 1 11.5
9 lymphoma, hodgkin, y-linked pseudoautosomal 11.5
10 lymphoma 11.5
11 lymphoproliferative syndrome 1 11.2
12 hodgkin's paragranuloma 11.2
13 hodgkin's granuloma 11.2
14 kidney rhabdoid cancer 10.3 PTPRC B3GAT1
15 gastric small cell carcinoma 10.3 PTPRC B3GAT1
16 testicular infarct 10.2 PTPRC PHYH
17 leukemia 10.1
18 b-cell lymphoma 10.1
19 immune deficiency disease 10.1
20 nephrotic syndrome 10.1
21 heart lymphoma 10.1 PTPRC BCL6
22 testicular lymphoma 10.1 PTPRC BCL6
23 ataxia and polyneuropathy, adult-onset 10.1
24 thrombocytopenia 10.1
25 breast cancer 10.1
26 deficiency anemia 10.1
27 neutropenia 10.1
28 acquired immunodeficiency syndrome 10.1
29 colon lymphoma 10.0 PTPRC BCL6
30 epidural neoplasm 10.0 PTPRC BCL6
31 anemia, autoimmune hemolytic 10.0
32 ataxia-telangiectasia 10.0
33 lymphoproliferative syndrome 10.0
34 lymphocytic leukemia 10.0
35 telangiectasis 10.0
36 purpura 10.0
37 hemolytic anemia 10.0
38 plasmablastic lymphoma 10.0 PTPRC BCL6
39 anaplastic large cell lymphoma 10.0
40 hypothyroidism 10.0
41 hypereosinophilic syndrome 10.0
42 cerebellar degeneration 10.0
43 mycosis fungoides 9.9
44 osteogenic sarcoma 9.9
45 follicular lymphoma 9.9
46 acute leukemia 9.9
47 thrombocytopenia due to platelet alloimmunization 9.9
48 splenic disease 9.9
49 histiocytosis 9.9
50 paraneoplastic cerebellar degeneration 9.9

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:



Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Symptoms & Phenotypes for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

UMLS symptoms related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:


fever, night sweats

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 BCL6 CR2 ERF PHYH PKP1 PTPRC
2 mortality/aging MP:0010768 9.1 B3GAT1 BCL6 CR2 ERF PKP1 PTPRC

Drugs & Therapeutics for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Drugs for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 415)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
3
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
4
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
5
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
6
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
7
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 441411 12560
8
Chlorambucil Approved Phase 3 305-03-3 2708
9
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
10
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
11
nivolumab Approved Phase 3 946414-94-4
12
Daunorubicin Approved Phase 3 20830-81-3 30323
13
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
14
rituximab Approved Phase 3 174722-31-7 10201696
15
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
16
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
17
Mycophenolic acid Approved Phase 3 24280-93-1 446541
18
tannic acid Approved Phase 3 1401-55-4
19
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
20
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
21
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
22
Gemcitabine Approved Phase 3 95058-81-4 60750
23
Vinblastine Approved Phase 3 865-21-4 241903 13342
24
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
25
Ifosfamide Approved Phase 3 3778-73-2 3690
26
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
27
Etoposide Approved Phase 3 33419-42-0 36462
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
30
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
31
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
32
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
33
Melphalan Approved Phase 3 148-82-3 460612 4053
34
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
35
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
36
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
37
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
38
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
39
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
41
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
42
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
43
Cortisone Experimental Phase 3 53-06-5 222786
44
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
45 Mitoguazone Investigational Phase 3 459-86-9
46 Interferon-alpha Phase 3
47 Interferon alpha-2 Phase 3
48 Epoetin alfa Phase 3 113427-24-0
49 Contraceptives, Oral Phase 3
50 Contraceptives, Oral, Combined Phase 3

Interventional clinical trials:

(show top 50) (show all 866)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
3 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
4 A Single Cohort Phase 4 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD Recruiting NCT03646123 Phase 4 brentuximab vedotin;doxorubicin;vinblastine;dacarbazine;G-CSF
5 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
6 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
7 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
8 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
9 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
10 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
11 Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
12 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
13 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
14 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
15 Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups Unknown status NCT00005584 Phase 3 ABVD regimen;BEACOPP regimen;epirubicin hydrochloride;prednisone;vinblastine sulfate
16 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
17 Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
18 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
19 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
20 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
21 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
22 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
23 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy Completed NCT00039910 Phase 3 (PN-152,243)/ PN-196,444
24 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT) Completed NCT01034163 Phase 3 Panobinostat;Placebo
25 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
26 Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
27 A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Completed NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
28 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
29 Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
30 A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed NCT00928018 Phase 3 Sirolimus;Methotrexate;Tacrolimus;Cyclosporine;MMF
31 Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
32 Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
33 A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
34 A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
35 A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
36 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy Completed NCT00261677 Phase 3 epoetin alfa
37 Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
38 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
39 A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
40 RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
41 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
42 Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population Completed NCT00838357 Phase 3 Generic = Plerixafor
43 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
44 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
45 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Completed NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
46 A PHASE III STUDY OF RADIOTHERAPY OR ABVD PLUS RADIOTHERAPY VERSUS ABVD ALONE IN THE TREATMENT OF EARLY STAGE HODGKIN'S DISEASE Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
47 The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
48 First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
49 Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812) Recruiting NCT03138499 Phase 3
50 HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD Recruiting NCT02661503 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Brentuximab Vedotin;Dacarbazine;Dexamethasone

Search NIH Clinical Center for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: hodgkin disease

Genetic Tests for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Anatomical Context for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards organs/tissues related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

41
T Cells, B Cells, Bone, Bone Marrow, Breast, Lung, Heart

Publications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Articles related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

(show top 50) (show all 1445)
# Title Authors PMID Year
1
The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. 38
30458690 2019
2
Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy. 38
31033793 2019
3
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. 38
31170519 2019
4
Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. 38
30322329 2019
5
Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue. 38
30770545 2019
6
Cancer Risk in Klippel-Trenaunay Syndrome. 38
31045469 2019
7
Hepatic Manifestations of Lymphoproliferative Disorders. 38
30947878 2019
8
Primary adrenal Hodgkin lymphoma. 38
30899496 2019
9
Proton beam therapy in pediatric oncology. 38
30531222 2019
10
Presentation and Outcomes of Childhood Cancer Patients at Uganda Cancer Institute. 38
31205984 2019
11
Acrokeratosis Can Be a Warning Sign of an Underlying Malignancy. 38
31157185 2019
12
Interest of FDG-PET in the Management of Mantle Cell Lymphoma. 38
31024918 2019
13
Vaccine-induced immune thrombocytopaenia purpura in autologous haematopoietic stem cell transplantation. 38
30647224 2018
14
Paracoccidioides brasiliensis Infection Mimicking Recurrent Hodgkin Lymphoma: A Case Report and Review of the Literature. 38
29476307 2018
15
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. 38
30358625 2018
16
Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis. 38
30112841 2018
17
Novel Pilot Curriculum for International Education of Lymphoma Management Using E-Contouring. 38
30241149 2018
18
Bone loss and hematological malignancies in adults: a pilot study. 38
29549514 2018
19
Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. 38
29616457 2018
20
F-18 FDG PET-CT Versus Contrast Enhanced CT in Detection of Extra Nodal Involvement in Patients with Lymphoma. 38
29962712 2018
21
A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. 38
29644723 2018
22
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 38
29872609 2018
23
Is Carotid Stiffness a Possible Surrogate for Stroke in Long-term Survivors of Childhood Cancer after Neck Radiotherapy? 38
30018516 2018
24
FDG Accumulation in the Lumen of the Gallbladder Without Related Pathology. 38
29485432 2018
25
Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT. 38
30042982 2018
26
Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique. 38
28557251 2018
27
Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. 38
29339629 2018
28
Acquired reactive perforating collagenosis associated with Hodgkin disease. 38
28691303 2017
29
Feasibility and Acceptability of a Web Site to Promote Survivorship Care in Survivors of Hodgkin Disease. 38
30657382 2017
30
Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation. 38
28646013 2017
31
Idiopathic Thrombocytopenia Purpura Masking Hodgkin Disease: A Paraneoplastic Syndrome or Simply a Mere Association? 38
29430236 2017
32
Head and Neck Lymphoma in an Iranian Population. 38
31328112 2017
33
Head and Neck Lymphoma in an Iranian Population. 38
29034220 2017
34
Hematologic Malignancies Are Associated With Adverse Perioperative Outcomes After Total Hip Arthroplasty. 38
28372919 2017
35
Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis. 38
28272287 2017
36
Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. 38
28143714 2017
37
Pulmonary toxicity following bleomycin use: A single-center experience. 38
28862210 2017
38
Web Exclusives. Annals Consult Guys - The Adult Survivor of Hodgkin Disease: Falling Through the Cracks. 38
28505658 2017
39
Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients. 38
27811123 2017
40
Prolonged Rhinovirus Shedding in a Patient with Hodgkin Disease. 38
28137315 2017
41
The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. 38
26310513 2017
42
Nivolumab in renal cell carcinoma: latest evidence and clinical potential. 38
28344662 2017
43
Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study. 38
27214265 2017
44
First Report on Stem Cell Transplant From Iraq. 38
28260453 2017
45
Emerging role of checkpoint blockade therapy in lymphoma. 38
28203344 2017
46
[Thoracic Endovascular Aortic Repair for a Descending Thoracic Aneurysm Associated with Pseudocoarctation of the Aorta;Report of a Case]. 38
28174405 2017
47
Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin - case study and brief literature review. 38
28680340 2017
48
Association between abnormal serum free light chains ratio and known prognostic factors in lymphoma; a nephrology viewpoint. 38
28497093 2017
49
[Cardiomyoblasts Produced from Mesenchymal Stem Cells in Complex Therapy of Heart Radiation Damage]. 38
30698926 2017
50
Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease. 38
27566884 2016

Variations for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Expression for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance.

Pathways for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Pathways related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.86 PTPRC CR2 BCL6
2
Show member pathways
11.52 PTPRC CR2 BCL6
3 10.52 PTPRC CR2 BCL6

GO Terms for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Biological processes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of B cell proliferation GO:0030890 9.16 PTPRC BCL6
2 B cell proliferation GO:0042100 8.96 PTPRC CR2
3 B cell differentiation GO:0030183 8.8 PTPRC CR2 BCL6

Molecular functions related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription repressor activity, RNA polymerase II-specific GO:0001227 8.62 ERF BCL6

Sources for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....